SCHEMBL2838274

SCHEMBL2838274

CCN1CCc2ccsc2C(Oc2cccc(Br)c2Cl)C1

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.34
PNMT P11086 1/20 0.32
HRH3 Q9Y5N1 1/20 0.31
SLC6A4 P31645 1/20 0.31
TAAR1 Q96RJ0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837042 0.89 SIGMAR1 (0.36) SIGMAR1TAAR1
SCHEMBL2841618 0.86 DRD1 (0.35) SIGMAR1
SCHEMBL2840576 0.84 DRD3 (0.36) SIGMAR1SLC6A4
SCHEMBL2839422 0.81 MEN1 (0.39) SIGMAR1HRH3
SCHEMBL2841690 0.75 OPRD1 (0.40) SIGMAR1PNMTSLC6A4
SCHEMBL2841599 0.75 SLC6A4 (0.32) SLC6A4
SCHEMBL2841048 0.75 HTR2C (0.35) PNMT
SCHEMBL2840148 0.74 DRD1 (0.41) SIGMAR1SLC6A4
SCHEMBL2844559 0.73 OPRD1 (0.37) SLC6A4
SCHEMBL2840583 0.73 IMPDH2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217031-B2 Heteroaryl derivatives NIPPON SHINYAKU CO., LTD. (JP) 2012-07-10 US disclosed
US-20100048537-A1 HETEROARYL DERIVATIVES NIPPON SHINYAKU CO., LTD. (JP) 2010-02-25 US disclosed
EP-2141168-A1 HETEROARYL DERIVATIVES Nippon Shinyaku Co., Ltd. (JP) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048537-A1 HETEROARYL DERIVATIVES OPRD1, OPRM1, OPRK1 SIGMAR1 25/4885PNMT 1313/4885HRH3 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.